NCT03911973 2024-06-07Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast CancersBig Ten Cancer Research ConsortiumPhase 1/2 Active not recruiting37 enrolled